Post by
Kondero on Jun 18, 2014 10:42am
Just my opinion .000000000
Since almost two years, HOLX did'nt show any eagerness to make the PCA3 test flare up. Probably because that company is dedicated to women diseases above all. Nevertheless, its subsidiary, Gen-Probe , has been in the past an allied in the PCA3 test development and among its knowledge the Panther technology ( and its links with General Electric) would be useful to CUR.
If the new multi-marker test is going to be a fondamental breakthrough providing crucial informations to cancer specialists with the strength of a dead certainty, then a firm much more powerful than HOLX could be very interested to be part of a trio with CUR and HOLX ; a company that is able to counter and fall back the PSA lobby ( damageable by the misuses of the PSA test) by its vast know-how in marketing .
As Chief Medical Officer , Yves Fradet has the scientific responsibility of that new test . The responsibility to solve that complex situation devolves upon Richard Bordeleau.
Finally , to make a long story short , let's say that CUR would need a signifiant upfront payment and fair royalties.
Fantomatus